The DOI matches its Crossref record; 177 of the 177 references it cites were found in a registry or an index.
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Open accessAbstract
OBJECTIVE: The authors conducted a systematic review and meta-analysis of ketamine and other N-methyl-d-aspartate (NMDA) receptor antagonists in the treatment of major depression. METHOD: Searches of MEDLINE, PsycINFO, and other databases were conducted for placebo-controlled, double-blind, randomized clinical trials of NMDA antagonists in the treatment of depression. Primary outcomes were rates of treatment response and transient remission of symptoms. Secondary outcomes included change in depression symptom severity and the frequency and severity of dissociative and psychotomimetic effects. Results for each NMDA antagonist were combined in meta-analyses, reporting odds ratios for dichotomous outcomes and standardized mean differences for continuous outcomes. RESULTS: Ketamine (seven trials encompassing 147 ketamine-treated participants) produced a rapid, yet transient, antidepressant effect, with odds ratios for response and transient remission of symptoms at 24 hours equaling 9.87 (4.37-22.29) and 14.47 (2.67-78.49), respectively, accompanied by brief psychotomimetic and dissociative effects. Ketamine augmentation of ECT (five trials encompassing 89 ketamine-treated participants) significantly reduced depressive symptoms following an initial treatment (Hedges' g=0.933) but not at the conclusion of the ECT course. Other NMDA antagonists failed to consistently demonstrate efficacy; however, two partial agonists at the NMDA coagonist site, d-cycloserine and rapastinel, significantly reduced depressive symptoms without psychotomimetic or dissociative effects. CONCLUSIONS: The antidepressant efficacy of ketamine, and perhaps D-cycloserine and rapastinel, holds promise for future glutamate-modulating strategies; however, the ineffectiveness of other NMDA antagonists suggests that any forthcoming advances will depend on improving our understanding of ketamine's mechanism of action. The fleeting nature of ketamine's therapeutic benefit, coupled with its potential for abuse and neurotoxicity, suggest that its use in the clinical setting warrants caution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Of note, however, rapastinel, another drug that reverses synaptic plasticity deficits and exhibits antidepressant-like effects in rodent models 36,37 , has been studied in 3 clinical trials to date with relatively weak evidence for its efficacy 38 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [38]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ketamine, an antagonist of the glutamatergic N-methyl-D-aspartate (NMDA) receptor (an ionotropic glutamate receptor), was shown to exhibit rapid onset and robust, short-term antidepressant effect in patients with treatment-resistant depression (TRD) [1–3].”
From Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Racemic ketamine was obtained from the Yale-New Haven Hospital Pharmacy and administered intravenously by constant infusion over 40 minutes at a dose of 0.5mg/kg, which has consistently been shown to have robust and rapid antidepressant effects 7,8 , and is typically used clinically.”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [8]
In the citing paper
“This is supported by the finding that other NMDA receptor antagonists such as memantine, lanicemine and nitrous oxide do not exert a consistent antidepressant effect in RCTs.90”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [90]
In the citing paper
“Ketamine's antidepressant effects compared to placebo controls are further supported by several thorough meta-analyses [134-136].”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [134]
In the citing paper
“This literature leads to the conclusion that while alternative NMDAR channel-blocking antagonists may exert clinical antidepressant actions, such actions are not of the same time frame or magnitude as those exerted by ketamine.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [99]
In the citing paper
“However, clinical trials indicate that these alternative NMDAR antagonists, lack the rapid, robust and/or long-lasting antidepressant actions of ketamine in humans 99.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 259
RetractedBias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,312
Publication and related bias in meta-analysis
Sterne, J. A. C., Gavaghan, D., & Egger, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00242-0 · Cited by 2,282
Blockade of NMDA Receptors and Apoptotic Neurodegeneration in the Developing Brain
Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vöckler, J., Dikranian, K., Tenkova, T. I., Stefovska, V., Turski, L., & Olney, J. W. (1999) · Science · doi:10.1126/science.283.5398.70 · Cited by 2,055
Peters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R., & Rushton, L. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.010 · Cited by 2,053
Flagged first, then by citations
Research works printed but not linked: 6
Cited by
Sorted by citations
Items 101–200 of 599
Liu, S., Li, T., Liu, H., Wang, X., Bo, S., Xie, Y., Bai, X., Wu, L., Wang, Z., & Liu, D. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.01.037 · Cited by 89
Ketamine treatment for refractory anxiety: A systematic review
Tully, J. L., Dahlén, A. D., Haggarty, C. J., Schiöth, H. B., & Brooks, S. J. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15374 · Cited by 95
Zhang, H., Huang, L., Zhong, Y.-B., Zhou, Q., Wang, H., Zheng, G., & Lin, Y. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00276 · Cited by 86
Aleksandrova, L. R., Wang, Y. T., & Phillips, A. G. (2020) · Molecular Brain · doi:10.1186/s13041-020-00627-z · Cited by 85
Price, R. B., Spotts, C., Panny, B., Griffo, A., Degutis, M., Cruz, N., Bell, E., Do-Nguyen, K., Wallace, M. L., Mathew, S. J., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220216 · Cited by 85
Brinck, E. C. V., Maisniemi, K., Kankare, J., Tielinen, L., Tarkkila, P. J., & Kontinen, V. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000004729 · Cited by 85
Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01465-2 · Cited by 78
“5 mg/kg, which has consistently been shown to have robust and rapid antidepressant effects [7, 8], and is typically used clinically.”
BackgroundResultSynthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites
Morris, P. J., Moaddel, R., Zanos, P., Moore, C. E., Gould, T., Zarate, C. A., & Thomas, C. J. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b02177 · Cited by 83
Zanos, P., Highland, J. N., Liu, X., Troppoli, T. A., Georgiou, P., Lovett, J., Morris, P. J., Stewart, B. W., Thomas, C. J., Thompson, S. M., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14683 · Cited by 82
Hidese, S., Ota, M., Wakabayashi, C., Noda, T., Ozawa, H., Okubo, T., & Kunugi, H. (2017) · Acta Neuropsychiatrica · doi:10.1017/neu.2016.33 · Cited by 81
Metabolomics of Major Depressive Disorder and Bipolar Disorder: Overview and Future Perspective
Hashimoto, K. (2018) · Advances in clinical chemistry · doi:10.1016/bs.acc.2017.12.005 · Cited by 81
Lazarevic, V., Yang, Y., Flais, I., & Svenningsson, P. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01246-3 · Cited by 81
Antidepressants for Pediatric Patients.
Dwyer, J. B., & Bloch, M. H. (2019) · PubMed · Cited by 85
Fountoulakis, K. Ν., Yatham, L. N., Grunze, H., Vieta, E., Young, A. H., Blier, P., Tohen, M. F., Kasper, S. F., & Moeller, H. J. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz064 · Cited by 81
Self-citationPennybaker, S. J., Niciu, M. J., Luckenbaugh, D. A., & Zarate, C. A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.10.026 · Cited by 76
Liwinski, T., Lang, U. E., Brühl, A. B., & Schneider, E. (2023) · Biomedicines · doi:10.3390/biomedicines11123128 · Cited by 82
Creatine for the Treatment of Depression
Kious, B. M., Kondo, D. G., & Renshaw, P. F. (2019) · Biomolecules · doi:10.3390/biom9090406 · Cited by 74
“Although recently much work in the pharmacological treatment of depression has been devoted to studying the potential of medications that alter the activity of the glutamatergic system—especially, the anesthetic agent ketamine and its enantiomer esketamine, which are potent antagonists of the N-methyl-D-aspartic acid…”
Investigational drugs in recent clinical trials for treatment-resistant depression
Garay, R. P., Zarate, C. A., Charpeaud, T., Citrome, L., Correll, C. U., Hameg, A., & Llorca, P. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1283217 · Cited by 76
Treatment-resistant depression: molecular mechanisms and management
Kajumba, M. M., Kakooza‐Mwesige, A., Nakasujja, N., Attix, D. K., & Canli, T. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00205-y · Cited by 93
Morrison, R. L., Fedgchin, M. M., Singh, J. B., van Gerven, J., Zuiker, R. G. J. A., Lim, K. S., van der Ark, P. D., Wajs, E., Xi, L., Zannikos, P., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4828-5 · Cited by 73
Emerging concepts on the use of ketamine for chronic pain
Yang, Y., Maher, D. P., & Cohen, S. P. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1717947 · Cited by 73
Bahji, A., Zarate, C. A., & Vázquez, G. H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047928 · Cited by 78
Shirayama, Y., & Hashimoto, K. (2016) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0718-1 · Cited by 75
Siegel, A. N., Di Vincenzo, J. D., Brietzke, E., Gill, H., Rodrigues, N. B., Lui, L. M. W., Teopiz, K. M., Ng, J., Ho, R., McIntyre, R. S., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.03.009 · Cited by 70
Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression
Wang, Y., Wang, X., Feng, S., Chen, N., Wang, Z., & Zhang, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105761 · Cited by 68
Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions
Riva-Posse, P., Reiff, C. M., Edwards, J. A., Job, G. P., Galendez, G. C., Garlow, S. J., Saah, T. C., Dunlop, B. W., & McDonald, W. M. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.025 · Cited by 70
Self-citationDoherty, T., Wajs, E., Melkote, R., Miller, J., Singh, J. B., & Weber, M. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00699-4 · Cited by 68
Liwinski, T., & Lang, U. E. (2023) · Nutrients · doi:10.3390/nu15173859 · Cited by 77
Li, J., Liu, L.-L., Su, W., Wang, B., Zhang, T., Zhang, Y., & Jiang, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.11.022 · Cited by 68
Ghazizadeh‐Hashemi, M., Ghajar, A., Shalbafan, M., Ghazizadeh‐Hashemi, F., Afarideh, M., Malekpour, F., Ghaleiha, A., Ardebili, M. E., & Akhondzadeh, S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.057 · Cited by 67
Riggs, L. M., Aracava, Y., Zanos, P., Fischell, J., Albuquerque, E. X., Pereira, E. F. R., Thompson, S. M., & Gould, T. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0443-3 · Cited by 66
Hollis, F., Mitchell, E. S., Cantó, C., Wang, D., & Sandi, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.017 · Cited by 68
Yokoyama, R., Higuchi, M., Tanabe, W., Tsukada, S., Naito, M., Yamaguchi, T., Chen, L., Kasai, A., Seiriki, K., Nakazawa, T., et al. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172876 · Cited by 65
Ketamine for Bipolar Depression: A Systematic Review
Bahji, A., Zarate, C. A., & Vázquez, G. H. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab023 · Cited by 70
Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences
Ballentine, G., Friedman, S. F., & Bzdok, D. (2022) · Science Advances · doi:10.1126/sciadv.abl6989 · Cited by 62
Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence
Subramanian, S., Haroutounian, S., Palanca, B. J. A., & Lenze, E. J. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120152 · Cited by 73
Milak, M. S., Rashid, R., Dong, Z., Kegeles, L. S., Grunebaum, M. F., Ogden, R. T., Lin, X., Mulhern, S. T., Suckow, R. F., Cooper, T. B., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13211 · Cited by 63
Onaolapo, A. Y., & Onaolapo, O. J. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i7.297 · Cited by 72
A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings
McInnes, L. A., Qian, J. J., Gargeya, R. S., DeBattista, C., & Heifets, B. D. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.097 · Cited by 63
Murrough, J. W., Stade, E., Sayed, S., Ahle, G., Kiraly, D. D., Welch, A., Collins, K. A., Soleimani, L., Iosifescu, D. V., & Charney, D. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.072 · Cited by 62
Carspecken, C. W., Borisovskaya, A., Lan, S.-T., Heller, K., Buchholz, J. R., Ruskin, D., & Rozet, I. (2018) · Journal of Neurosurgical Anesthesiology · doi:10.1097/ana.0000000000000511 · Cited by 64
Tian, Z. R., Dong, C., Fujita, A., Fujita, Y., & Hashimoto, K. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.07.003 · Cited by 63
Yoshida, K., Drew, M. R., Kono, A., Mimura, M., Takata, N., & Tanaka, K. F. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-00990-y · Cited by 55
(R)-ketamine as prophylactic and therapeutic drug for neurological disorders: Beyond depression
Wang, X., Yang, J., & Hashimoto, K. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104762 · Cited by 62
Henderson, T. A., & Morries, L. D. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00187 · Cited by 60
Bridging Rapid and Sustained Antidepressant Effects of Ketamine
Kim, J.-W., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.003 · Cited by 59
Ma, M., Ren, Q., Yang, C., Zhang, J.-C., Yao, W., Dong, C., Ohgi, Y., Futamura, T., & Hashimoto, K. (2016) · Scientific Reports · doi:10.1038/srep39209 · Cited by 60
Update on pharmacological management of procedural sedation for children
Roback, M. G., Carlson, D. W., Babl, F. E., & Kennedy, R. M. (2016) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000316 · Cited by 59
Banov, M. D., Young, J. R., Dunn, T., & Szabo, S. T. (2019) · CNS Spectrums · doi:10.1017/s1092852919001238 · Cited by 62
Molecular Basis of Late-Life Depression
Kuo, C.-Y., Lin, C., & Lane, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147421 · Cited by 62
Lv, S., Yao, K., Zhang, Y., & Zhu, S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109378 · Cited by 60
Zorumski, C. F., Nagele, P., Mennerick, S., & Conway, C. R. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00172 · Cited by 57
Update on GPCR-based targets for the development of novel antidepressants
Mantas, I., Saarinen, M., Xu, Q., & Svenningsson, P. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01040-1 · Cited by 61
Whittaker, E., Dadabayev, A. R., Joshi, S. A., & Glue, P. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211056743 · Cited by 56
The rapid anti-suicidal ideation effect of ketamine: A systematic review
Hochschild, A., Grunebaum, M. F., & Mann, J. J. (2021) · Preventive Medicine · doi:10.1016/j.ypmed.2021.106524 · Cited by 55
Cheng, X., Wang, H., Diao, M., & Jiao, H. (2022) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2022.04.028 · Cited by 55
Levinstein, M. R., Budinich, R. C., Bonaventura, J., Schatzberg, A. F., Zarate, C. A., & Michaelides, M. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240378 · Cited by 58
Kim, J., & Monteggia, L. M. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112378 · Cited by 56
HCN Channel Targets for Novel Antidepressant Treatment
Ku, S. M., & Han, M.-H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0538-7 · Cited by 54
Fujita, A., Fujita, Y., Pu, Y., Chang, L., & Hashimoto, K. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05346-5 · Cited by 53
Sex differences in resilience: Experiential factors and their mechanisms
Fallon, I. P., Tanner, M. K., Greenwood, B. N., & Baratta, M. V. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14639 · Cited by 62
Han, Y. S., Heuermann, R. J., Lyman, K. A., Fisher, D. W., Ismail, Q.-A., & Chetkovich, D. M. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.99 · Cited by 54
The neurophysiology of ketamine: an integrative review
McMillan, R. L., & Muthukumaraswamy, S. D. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0090 · Cited by 51
Li, D.-J., Wang, F.-C., Chu, C.-S., Chen, T.-Y., Tang, C.-H., Yang, W.-C., Chow, P. C.-K., Wu, C.-K., Tseng, P.-T., & Lin, P.-Y. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.11.008 · Cited by 51
Trevlopoulou, A., Touzlatzi, N., & Pitsikas, N. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4181-x · Cited by 54
Esterlis, I., Holmes, S. E., Sharma, P., Krystal, J. H., & DeLorenzo, C. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.025 · Cited by 50
Lack of metabolism in (R)-ketamine’s antidepressant actions in a chronic social defeat stress model
Zhang, K., Fujita, Y., & Hashimoto, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-22449-9 · Cited by 50
Past, present, and future of nitrous oxide
Lew, V. K., McKay, E. A., & Maze, M. (2017) · British Medical Bulletin · doi:10.1093/bmb/ldx050 · Cited by 50
Ma, L., Zhang, J., Fujita, Y., Qu, Y., Shan, J., Wan, X., Wang, X., Ishima, T., Kobayashi, K., Wang, L., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01803-6 · Cited by 52
Adult neuroplasticity: A new “cure” for major depression?
Albert, P. R. (2019) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.190072 · Cited by 61
Ho, M.-F., Correia, C., Ingle, J. N., Kaddurah-Daouk, R., Wang, L., Kaufmann, S. H., & Weinshilboum, R. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.03.032 · Cited by 49
Targeting metaplasticity mechanisms to promote sustained antidepressant actions
Brown, K. A., & Gould, T. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02397-1 · Cited by 49
Dwyer, J. B., Landeros‐Weisenberger, A., Johnson, J. A., Tobón, A. L., Flores, J. M., Nasir, M., Couloures, K. G., Sanacora, G., & Bloch, M. H. (2022) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.22020004 · Cited by 50
A Meta-Analysis of Memantine for Depression
Kishi, T., Matsunaga, S., & Iwata, N. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161251 · Cited by 49
Ketamine as a Treatment for Adolescent Depression: A Case Report
Dwyer, J. B., Beyer, C., Wilkinson, S. T., Ostroff, R. B., Qayyum, Z., & Bloch, M. H. (2017) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2017.01.006 · Cited by 49
Zhang, K., Dong, C., Fujita, Y., Fujita, A., & Hashimoto, K. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx100 · Cited by 50
Xiong, Z., Fujita, Y., Zhang, K., Pu, Y., Chang, L., Ma, M., Chen, J., & Hashimoto, K. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.111904 · Cited by 49
Ketamine’s rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors
Zaytseva, A., Bouckova, E., Wiles, M. J., Wustrau, M. H., Schmidt, I. G., Mendez-Vazquez, H., Khatri, L., & Kim, S. (2023) · eLife · doi:10.7554/elife.86022 · Cited by 48
Selective basal ganglia vulnerability to energy deprivation: Experimental and clinical evidences
Tambasco, N., Romoli, M., & Calabresi, P. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.07.003 · Cited by 48
Kohtala, S., Alitalo, O., Rosenholm, M., Rozov, S. V., & Rantamäki, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107741 · Cited by 47
Therapeutic potential of ketamine for alcohol use disorder
Worrell, S. D., & Gould, T. J. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.05.006 · Cited by 47
Wang, Y., Zhang, N., Liu, L., Jiang, H., Hu, D., Wang, Z., Chen, N., & Zhang, Y. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.01.024 · Cited by 50
Duan, W., Peng, K., Qin, H.-M., Li, B.-M., Xu, Y.-X., Wang, D.-J., Yu, L., Wang, H., Hu, J., & Wang, Q. (2023) · British Journal of Anaesthesia · doi:10.1016/j.bja.2023.10.038 · Cited by 47
Mathew, S. J., Gueorguieva, R. V., Brandt, C., D, M. F. M., & Sanacora, G. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.106 · Cited by 46
Astrocytes in rapid ketamine antidepressant action
Stenovec, M., Li, B., Verkhratsky, A., & Zorec, R. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108158 · Cited by 52
Lactobacillus rhamnosus: An emerging probiotic with therapeutic potential for depression
Feng, J. B., Cen, Q., Cui, Y., Hu, X., Li, M., Wang, L., Wei, J., Sun, N., Wang, J., & Zhang, A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107541 · Cited by 51
Lasič, E., Lisjak, M., Horvat, A., Božić, M., Šakanović, A., Anderluh, G., Verkhratsky, A., Vardjan, N., Jorgačevski, J., Stenovec, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47459-z · Cited by 48
Matraszek, R., Chwil, M., Terlecka, P., & Skoczylas, M. M. (2019) · Pharmaceuticals · doi:10.3390/ph12040172 · Cited by 50
An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine
Berardis, D. D., Tomasetti, C., Pompili, M., Serafini, G., Vellante, F., Fornaro, M., Valchera, A., Perna, G., Volpe, U., Martinotti, G., et al. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200131100316 · Cited by 46
Cardoner, N., Andero, R., Cano, M., Marin-Blasco, I., Porta-Casteràs, D., Serra-Blasco, M., Via, E., Vicent-Gil, M., & Portella, M. J. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230703091435 · Cited by 45
Nagy, C., Vaillancourt, K., & Turecki, G. (2017) · Genes Brain & Behavior · doi:10.1111/gbb.12446 · Cited by 47
(R)‐ and (S)‐ketamine induce differential fMRI responses in conscious rats
Masaki, Y., Kashiwagi, Y., Watabe, H., & Abe, K. (2019) · Synapse · doi:10.1002/syn.22126 · Cited by 44
Predicting and Managing Treatment Non-response in Posttraumatic Stress Disorder
Fonzo, G. A., Federchenco, V., & Lara, A. E. (2020) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-020-00203-1 · Cited by 49
Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials
Raupp, I. M., Vital, M. A. B. F., Galduróz, J. C. F., & Andreatini, R. (2018) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2017-2393 · Cited by 44
Engaging homeostatic plasticity to treat depression
Workman, E. R., Niere, F., & Raab‐Graham, K. F. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.225 · Cited by 43
Ketamine-based anesthesia improves electroconvulsive therapy outcomes: a randomized-controlled study
Gamble, J. J., Bi, H., Bowen, R., Weisgerber, G., Sanjanwala, R., Prasad, R., & Balbuena, L. (2018) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-018-1088-0 · Cited by 43
Brenner, P., Brandt, L., Li, G., DiBernardo, A., Bodén, R., & Reutfors, J. (2019) · Addiction · doi:10.1111/add.14596 · Cited by 42
Brenner, P., Brandt, L., Li, G., DiBernardo, A., Bodén, R., & Reutfors, J. (2019) · Addiction · doi:10.1111/add.14866 · Cited by 43
Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives
Shin, C., & Kim, Y. (2020) · Psychiatry Investigation · doi:10.30773/pi.2019.0236 · Cited by 47
Ketamine for Treatment of Mood Disorders and Suicidality: A Narrative Review of Recent Progress
Kritzer, M. D., Mischel, N., Young, J. R., Lai, C. S., Masand, P. S., Szabo, S. T., & Mathew, S. J. (2021) · Annals of Clinical Psychiatry · doi:10.12788/acp.0048 · Cited by 43
Metadata
- Authors
- Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments
- Affiliations
- University of Miami (US)
- University of Iowa (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2015-10-01
- Volume
- 172
- Issue
- 10
- Pages
- 950-966
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2111728433
- Semantic Scholar
- 1554f1974f06fcabaaf6be07d58e1ebf23572172
- Cited by
- 598
- References
- 177
- Citations by year
- 2026: 27 · 2025: 36 · 2024: 37 · 2023: 50 · 2022: 53 · 2021: 65 · 2020: 62 · 2019: 65 · 2018: 71 · 2017: 64 · 2016: 62 · 2015: 5
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Foundation for Suicide Prevention
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Teva Pharmaceutical Industries
- Brown University
- Celgene
- University of Miami
- Emory University
- Sunovion
- National Alliance for Research on Schizophrenia and Depression
- OPKO Health
- University of Oxford
- Mitsubishi Tanabe Pharma Corporation
- H. Lundbeck A/S
- National Institutes of Health
- Health Resources and Services Administration
- School of Medicine, Emory University
- Allergan
- Leonard M. Miller School of Medicine
- Roy J. and Lucille A. Carver College of Medicine, University of Iowa
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- ketamine, NMDA receptor antagonists, major depressive disorder, antidepressant efficacy, rapid-acting antidepressants, D-cycloserine, psychotomimetic effects, dissociative effects, glutamate modulation, treatment response, remission
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Humans, Ketamine, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
